Literature DB >> 19902430

VEGFR2 is selectively expressed by FOXP3high CD4+ Treg.

Hiroyuki Suzuki1, Hideya Onishi, Junji Wada, Akio Yamasaki, Haruo Tanaka, Kenji Nakano, Takashi Morisaki, Mitsuo Katano.   

Abstract

CD25+ FOXP3+CD4+ T cells (Treg) have been considered to play an important role in immune tolerance against several tumor antigens. It has also been indicated that high-level expression of FOXP3 (FOXP3high) is sufficient to confer suppressive activity to normal non-Treg. Here, we showed for the first time that vascular endothelial growth factor receptor 2 (VEGFR2) is selectively expressed by FOXP3high but not FOXP3low Treg. Such VEGFR2+ Treg exist in several tissues including PBMC and malignant effusion-derived lymphocytes. In conclusion, VEGFR2 may be a novel target for controlling Treg with highly suppressive function.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 19902430     DOI： 10.1002/eji.200939887

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN： 0014-2980            Impact factor:   5.532


  52 in total

1.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

Review 2.  Targeted complement inhibition and microvasculature in transplants: a therapeutic perspective.

Authors:  M A Khan; J L Hsu; A M Assiri; D C Broering
Journal:  Clin Exp Immunol       Date:  2015-11-05       Impact factor: 4.330

3.  Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice.

Authors:  Dhanalakshmi Chinnasamy; Zhiya Yu; Marc R Theoret; Yangbing Zhao; Rajeev K Shrimali; Richard A Morgan; Steven A Feldman; Nicholas P Restifo; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2010-10-11       Impact factor: 14.808

Review 4.  T-regulatory cell-mediated immune tolerance as a potential immunotherapeutic strategy to facilitate graft survival.

Authors:  Mohammad A Khan; Sana Moeez; Suhail Akhtar
Journal:  Blood Transfus       Date:  2013-05-07       Impact factor: 3.443

5.  Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein.

Authors:  Tory P Johnson; Karan Patel; Kory R Johnson; Dragan Maric; Peter A Calabresi; Rodrigo Hasbun; Avindra Nath
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-29       Impact factor: 11.205

Review 6.  Anti-angiogenic and macrophage-based therapeutic strategies for glioma immunotherapy.

Authors:  Eiichi Ishikawa; Tsubasa Miyazaki; Shingo Takano; Hiroyoshi Akutsu
Journal:  Brain Tumor Pathol       Date:  2021-05-11       Impact factor: 3.298

Review 7.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

8.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

9.  Secretory factors produced by adipose mesenchymal stem cells downregulate Th17 and increase Treg cells in peripheral blood mononuclear cells from rheumatoid arthritis patients.

Authors:  Georgi Vasilev; Mariana Ivanova; Ekaterina Ivanova-Todorova; Kalina Tumangelova-Yuzeir; Ekaterina Krasimirova; Rumen Stoilov; Dobroslav Kyurkchiev
Journal:  Rheumatol Int       Date:  2019-04-03       Impact factor: 2.631

10.  Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo.

Authors:  S Yasuda; M Sho; I Yamato; H Yoshiji; K Wakatsuki; S Nishiwada; H Yagita; Y Nakajima
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.